The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis-Reference-Cited by-同舟云学术

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis

Published:2018-07-28 Issue:1 Volume:19 Page:
ISSN:1465-993X
Container-title:Respiratory Research
language:en
Short-container-title:Respir Res

Author:

Guenther Andreas,Krauss Ekaterina,Tello Silke,Wagner Jasmin,Paul Bettina,Kuhn Stefan,Maurer Olga,Heinemann Sabine,Costabel Ulrich,Barbero María Asunción Nieto,Müller Veronika,Bonniaud Philippe,Vancheri Carlo,Wells Athol,Vasakova Martina,Pesci Alberto,Sofia Matteo,Klepetko Walter,Seeger Werner,Drakopanagiotakis Fotios,Crestani Bruno

Funder

European IPF Network FP7 Program

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/s12931-018-0845-5.pdf

Reference39 articles.

1. Martinez FJ, et al. The diagnosis of idiopathic pulmonary fibrosis: current and future approaches. Lancet Respir Med. 2017;5(1):61–71.

2. Jo HE, et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian idiopathic pulmonary fibrosis registry. Eur Respir J. 2017;49(2). https://doi.org/10.1183/13993003.01592-2016 .

3. Hutchinson J. Idiopathic pulmonary fibrosis: another step in understanding the burden of this disease. Eur Respir J. 2016;48(1):26–8.

4. Lee HE, et al. Incidence and prevalence of idiopathic interstitial pneumonia and idiopathic pulmonary fibrosis in Korea. Int J Tuberc Lung Dis. 2016;20(7):978–84.

5. Albera C, et al. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J. 2016;48(3):843–51.

Cited by 221 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proteomic signatures improve risk prediction for common and rare diseases;Nature Medicine;2024-07-22

2. Influencia de las guías de práctica clínica en el diagnóstico y tratamiento de la fibrosis pulmonar idiopática. Datos del Registro de la Sociedad Española de Neumología y Cirugía Torácica;Open Respiratory Archives;2024-07

3. Tolerability and efficacy of switching anti-fibrotic treatment from nintedanib to pirfenidone for idiopathic pulmonary fibrosis;PLOS ONE;2024-06-13

4. What has antifibrotic therapy changed for patients with idiopathic pulmonary fibrosis;Meditsinskiy sovet = Medical Council;2024-06-05

5. Assessment of the impact of social deprivation, distance to hospital and time to diagnosis on survival in idiopathic pulmonary fibrosis;Respiratory Medicine;2024-06